A team of researchers has demonstrated that a liquid biopsy measuring epigenetic changes may provide a noninvasive way to classify subtypes of small-cell lung cancer (SCLC), a condition where obtaining tumor tissue is frequently impractical. The method, known as cfChIP-seq, isolates nucleosomes found in blood and examines histone modifications associated with active genes, producing a snapshot of the tumor’s transcriptional activity.
Plasma-based epigenetic analysis
Developed through collaboration between Hebrew University of Jerusalem, the National Cancer Institute, Hadassah-Hebrew University Medical Center, Northwestern University, and affiliated institutions, this technique analyzed hundreds of plasma samples. Their findings revealed chromatin signals tied to key transcription factors, ASCL1, NEUROD1, POU2F3, and ATOH1, that define SCLC subtypes.
When researchers compared plasma data with RNA sequencing from matching tumor samples, the chromatin patterns aligned closely with gene expression linked to those subtypes. This suggests that SCLC operates as a collection of distinct transcriptional states rather than a single disease entity. If validated, the approach could shift monitoring from static genetic profiles to a real-time assessment of tumor biology, potentially informing treatment choices.
Previous blood-based methods focused on DNA methylation or nucleosome positioning. In contrast, cfChIP-seq directly enriches nucleosomes marked by active histone modifications, allowing it to infer gene activity rather than just DNA structure or sequence. This capability may also detect tumor heterogeneity. Some patients exhibited plasma signals for both ASCL1 and NEUROD1 simultaneously, implying that circulating material could capture the diversity of metastatic sites often overlooked by single-biopsy sampling.
The study’s primary goal was to establish technical feasibility. Investigators emphasize that larger clinical trials, assay standardization, and direct comparisons with tissue samples are essential next steps. While shifts in plasma subtype signals might reflect true tumor evolution, they could also stem from variations in tumor-derived DNA levels in the bloodstream.
Repeated blood tests could prove particularly useful during relapse, when obtaining fresh tumor tissue is especially challenging. The researchers conclude that their findings provide a foundation for applying noninvasive transcriptional subtyping in clinical practice. Should further validation succeed, plasma chromatin profiling might enable clinicians to track SCLC progression under treatment and match evolving tumor states with targeted therapies.
Leave a Reply